Crinetics Pharmaceuticals (CRNX) Misses Q3 EPS by 14c

Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q3 EPS of ($1.01), $0.14 worse than the analyst estimate of ($0.87). Revenue for the quarter came in at $350 thousand versus the consensus estimate of $123.5 thousand.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• Espey Manufacturing (ESP) Tops Q4 EPS by 24c
• KB Home (KBH) PT Lowered to $50 at RBC Capital